Genfit ( (GNFT) ) has released its Q4 earnings. Here is a breakdown of the information Genfit presented to its investors.
Genfit is a late-stage biopharmaceutical company focused on developing treatments for rare and life-threatening liver diseases, with a strong emphasis on Acute-on-Chronic Liver Failure (ACLF) and a diverse pipeline of therapeutic assets.
In its 2024 financial results, Genfit reported a net profit of €1.5 million, marking a significant turnaround from a loss in the previous year. This positive outcome was largely driven by the commercial launch of Iqirvo® for Primary Biliary Cholangitis (PBC) in the U.S. and Europe, which resulted in a milestone payment of €48.7 million.
Key highlights from the report include the successful regulatory approvals and commercial launch of Iqirvo® in major markets, as well as substantial progress in Genfit’s ACLF programs. The company has initiated a major Real-World data program to enhance understanding of ACLF, and significant advancements have been made in their pipeline, including the development of new formulations and clinical trials for various assets.
Financially, Genfit strengthened its position with a non-dilutive royalty financing agreement worth up to €185 million, which has extended its cash runway beyond 2027. The company also successfully repurchased 99% of its outstanding convertible debt, reducing financial burdens and enhancing shareholder value.
Looking ahead, Genfit is poised to continue its momentum with further developments in its ACLF programs and other therapeutic areas. The company remains committed to advancing its pipeline and achieving key milestones in 2025, with a focus on expanding its market presence and enhancing patient outcomes.